AR Isolate Bank – Year 3 – Customer Satisfaction Survey for CDC AR Isolate Bank Form Approved
OMB Control No.: 0920-1071
Exp. Date: 2/28/2021
REQUEST TO CUSTOMER—FIRST WAVE:
FROM: [email protected]
TO: POCs from order list
SUBJECT: 10-min survey about AR Isolate Bank
Dear AR Isolate Bank customer,
The CDC and FDA Antibiotic Resistance Isolate Bank (AR Isolate Bank) launched in July 2015 and, as we hit our three-year mark, we would like to hear feedback on how this resource has provided value to your organization and how it can be improved. Your feedback will help us build a collection of the most useful isolates in the fight against antibiotic resistance.
Take the 10-minute survey here: [LINK]
The survey will close [DATE].
With your permission, we may contact you based on your responses to develop success stories that will be published on our website and in other CDC and FDA materials.
On behalf of CDC and FDA, we appreciate your participation in this survey.
Best,
Jean B. Patel, PhD, D(ABMM)
Health Scientist, Antibiotic Resistance Coordination and Strategy Unit
Centers for Disease Control and Prevention
Ribhi
M. Shawar, Ph.D, D(ABMM)
Branch Chief
General
Bacteriology and Antimicrobial Susceptibility Branch
CDRH/OIR
Division of Microbiology Devices
Food
and Drug Administration
[email protected]
REQUEST TO CUSTOMER—SECOND WAVE:
FROM: [email protected]
TO: POCs from order list
SUBJECT: How is the AR Isolate Bank doing?
Dear AR Isolate Bank customer,
This is a reminder that the CDC and FDA Antibiotic Resistance Isolate Bank satisfaction survey will close [DATE].
Please take 10 minutes to complete the survey and provide feedback on how it has provided value to your organization and how it can be improved.
Take the survey now: [LINK]
With your permission, we may contact you based on your responses to develop success stories that will be published on our website and in other CDC and FDA materials.
On behalf of CDC and FDA, we appreciate your participation in this survey. Your feedback will help us build a repository of the most useful isolates in the fight against antibiotic resistance.
Best,
Jean B. Patel, PhD, D(ABMM)
Health Scientist, Antibiotic Resistance Coordination and Strategy Unit
Centers for Disease Control and Prevention
Ribhi
M. Shawar, Ph.D, D(ABMM)
Branch Chief
General
Bacteriology and Antimicrobial Susceptibility Branch
CDRH/OIR
Division of Microbiology Devices
Food
and Drug Administration
[email protected]
SURVEY HOSTED ON:
SurveyMonkey.com
INTRODUCTION:
Thank
you for providing feedback on the CDC and FDA Antibiotic Resistance
Isolate Bank.
The purpose of the survey is to capture how
the AR Isolate Bank has provided value to customers and how it can be
improved.
The information gathered from this survey will
not be published and will only inform next steps of implementation.
PROPOSED QUESTIONS:
Have you ordered from the AR Isolate Bank within the last year (August 2017 – August 2018)? If no, why not?
Yes
No [open-ended]
Which option below best describes your organization? [can select only one]
Academic (non-clinical)
Clinical laboratory (e.g., academic medical center, VA hospital, private hospital, public hospital, private laboratory, or reference laboratory)
Diagnostic manufacturer
Pharmaceutical manufacturer
Federal agency
Public health laboratory (city, county, or state)
Other (please describe)
How did you first hear about the AR Isolate Bank? [can select only one]
CDC website
FDA website
FDA request or suggestion to support a regulatory submission
Colleague
CLSI webinar
Publication
Scientific Conference/Meeting [open-ended]
Other: [open-ended]
Since August 2017, what AR Isolate Bank panels did you/your organization order? Check all that apply.
Since August 2017, how often have you/your organization ordered panels from the AR Isolate Bank? [can only select one]
1 occasion
2-5 occasions
6-9 occasions
10 occasions or more
How has your organization used the panels from the AR Isolate Bank? Check all that apply.
To develop (research, challenge, accelerate) a diagnostic device, test, or assay
To satisfy a specific request and/or support an application to FDA
To validate a diagnostic test for implementation in my laboratory
To develop (research, challenge, accelerate) an antimicrobial Other: [open-ended]
Based on your answer to Question #6, please provide more detail about how you have used the panels from the AR Isolate Bank. Please do not provide proprietary information. General descriptions for how the isolates helped improve process, increase product accuracy, meet organization priorities, add value, or support other AR strategies are appreciated. If you have not yet used the isolates, please explain how you intend to use them in the future. [open-ended]
Please take a moment to think about the AR Isolate Bank panels you received. Rate satisfaction with the following during your experience. [Likert scale: Very dissatisfied, Dissatisfied, Neither Dissatisfied nor Satisfied, Satisfied, Very satisfied, Not applicable]
Diversity of panels
Diversity of isolates available
Data available for isolates/panels
Descriptions of panel organisms
Viability of organisms
Confirmatory testing in your lab corresponded to isolate description
Troubleshooting problems with panels or isolates
Please comment on ratings given above about satisfaction with panels. [open-ended]
CDC and FDA are working together to expand the AR Isolate Bank collection. What additional isolate panels or information would be valuable to you/your organization in the future? How can the current collection be improved? If you have ordered isolates from other organizations, what was most valuable about that experience? [open-ended]
Please take a moment to think about the AR Isolate Bank ordering process. Rate satisfaction with the following during your experience. [Likert scale: Very dissatisfied, Dissatisfied, Neutral, Satisfied, Very satisfied, Not applicable]
Responsiveness of AR Isolate Bank staff if contacted
Duration of entire process (from initial order to delivery)
Ease of navigation through the AR Isolate Bank website
Please comment on ratings given above about satisfaction with panels. [open-ended]
CDC and FDA recently updated the AR Isolate Bank website, including adding new features. Have you visited the new AR Isolate Bank website? [can only select one]
Yes
No
Rate your satisfaction with the following AR Isolate Bank website features. [Likert scale: Very dissatisfied, Dissatisfied, Neither Dissatisfied nor Satisfied, Satisfied, Very satisfied, Not applicable]
Ability to create a customer profile
Order tracking
Order instructions provided on the website
AR Isolate Bank search feature
Metadata provided with isolates
Other: [open-ended]
Is there anything else you would like to tell us about your experiences using the AR Isolate Bank or the new website? If yes, please list.
Yes [open-ended]
No
Has any of the work you have done using isolates from the AR Isolate Bank contributed to a scientific publication, presentation or regulatory submission? If yes, please list.
Yes [open-ended]
No
Can we contact you for additional information? To improve the AR Isolate Bank overall and develop success stories, we would like to contact some customers for more information about their experience. We will NOT publish responses provided in this survey or confidential, proprietary information. [can select only one]
If yes, please provide your name and email address. [open-ended]
Public
reporting burden of this collection of information is estimated to
average 10 minutes per response, including the time for reviewing
instructions, searching existing data sources, gathering and
maintaining the data needed, and completing and reviewing the
collection of information. An agency may not conduct or sponsor,
and a person is not required to respond to a collection of
information unless it displays a currently valid OMB Control Number.
Send comments regarding this burden estimate or any other aspect of
this collection of information, including suggestions for reducing
this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton
Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA 0920-1071
| File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
| Author | Katy Capers |
| File Modified | 0000-00-00 |
| File Created | 2021-01-20 |